A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Sponsor
Chinese Academy of Medical Sciences
Study ID
NCT04447274
Phase
PHASE2
Status
Unknown

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab and Apatinib — DRUG
    Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles

Study Details

This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and Alveolar Soft Tissue Sarcoma (ASPS) . The purpose of this study was to evaluate the safety and efficacy of combination of Camrelizumab and Apatinib in the treatment of unresectable UPS and ASPS

Key Dates

Start date
Jul 1, 2020
Status verified
Jun 2020
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab and Apatinib
    Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Primary Outcome Measure

Progression-free rate at 12 weeks (PFR 12weeks) [ Time Frame: 12 weeks ]

Central Contacts

Related Studies